Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic

Abstract The U.S. has the tools to end the HIV epidemic, but progress has stagnated. A major gap in U.S. efforts to address HIV is the under-utilization of medications that can virtually eliminate acquisition of the virus, known as pre-exposure prophylaxis (PrEP). This document proposes a financing and delivery system to unlock broad access to PrEP for those most vulnerable to HIV acquisition and bring an end to the HIV epidemic.

[1]  P. Sullivan,et al.  America’s HIV Epidemic Analysis Dashboard: Protocol for a Data Resource to Support Ending the HIV Epidemic in the United States , 2022, JMIR public health and surveillance.

[2]  Michael E. Ohl,et al.  Bringing Iowa TelePrEP to Scale: A Qualitative Evaluation. , 2021, American journal of preventive medicine.

[3]  D. Apollonio,et al.  An observational survey assessing the extent of PrEP and PEP furnishing in San Francisco Bay Area pharmacies. , 2021, Journal of the American Pharmacists Association : JAPhA.

[4]  K. Mayer,et al.  Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide for Human Immunodeficiency Virus Preexposure Prophylaxis at a Boston Community Health Center , 2021, Open forum infectious diseases.

[5]  J. Doshi,et al.  Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA , 2021, AIDS.

[6]  David Bruce Lewis,et al.  Long-term protection from HIV infection with oral HIV pre-exposure prophylaxis in gay and bisexual men: findings from the expanded and extended EPIC-NSW prospective implementation study. , 2021, The lancet. HIV.

[7]  D. Smith,et al.  Persistence With Human Immunodeficiency Virus Pre-exposure Prophylaxis in the United States, 2012-2017. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  H. Orom,et al.  A Review of Cultural Influences on Risk for HIV and Culturally-Responsive Risk Mitigation Strategies Among African Immigrants in the US , 2021, Journal of Immigrant and Minority Health.

[9]  David R. Holtgrave,et al.  Effect of Medicaid Expansions on HIV Diagnoses and Pre-Exposure Prophylaxis Use. , 2021, American journal of preventive medicine.

[10]  K. Ghanem,et al.  Awareness of and Interest in Pre-Exposure Prophylaxis among Patients Receiving Services at Public Sexually Transmitted Disease Clinics in an Urban Setting , 2021, Journal of health care for the poor and underserved.

[11]  B. deCastro,et al.  Pre-exposure Prophylaxis (PrEP) Awareness and Prescribing Behaviors Among Primary Care Providers: DocStyles Survey, 2016–2020, United States , 2020, AIDS and Behavior.

[12]  S. Bellamy,et al.  Integrating HIV pre-exposure prophylaxis with community-based syringe services for women who inject drugs: Results from the Project SHE demonstration study. , 2020, Journal of acquired immune deficiency syndromes.

[13]  D. Karletsos,et al.  Impact of Medicaid Expansion on PrEP Utilization in the US: 2012–2018 , 2020, AIDS and Behavior.

[14]  R. Shrestha,et al.  National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 , 2020, Annals of Internal Medicine.

[15]  D. Smith,et al.  Initiation, discontinuation, and restarting HIV pre-exposure prophylaxis: ongoing implementation strategies. , 2020, The lancet. HIV.

[16]  Mary E Hawk,et al.  Intimate Partner Violence, HIV Pre-Exposure Prophylaxis (PrEP) Acceptability, and Attitudes About Use: Perspectives of Women Seeking Care at a Family Planning Clinic , 2020, AIDS and Behavior.

[17]  W. Steward,et al.  Improving the HIV PrEP continuum of care using an intervention for healthcare providers: a stepped-wedge study protocol , 2020, BMJ Open.

[18]  L. Bowleg,et al.  Intersectional social control: The roles of incarceration and police discrimination in psychological and HIV-related outcomes for Black sexual minority men. , 2020, Social science & medicine.

[19]  S. Reisner,et al.  HIV Testing and PrEP Use in a National Probability Sample of Sexually Active Transgender People in the United States. , 2020, Journal of acquired immune deficiency syndromes.

[20]  Allan E. Rodriguez,et al.  Interest in linkage to PrEP among people who inject drugs accessing syringe services; Miami, Florida , 2020, PloS one.

[21]  T. Frieden.  CDC , 2020, Catalysis from A to Z.

[22]  Michael R. Kramer,et al.  Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018. , 2020, Annals of epidemiology.

[23]  R. Walensky,et al.  Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV Preexposure Prophylaxis , 2020, Annals of Internal Medicine.

[24]  E. Vittinghoff,et al.  Understanding PrEP Persistence: Provider and Patient Perspectives , 2020, AIDS and Behavior.

[25]  G. Tao,et al.  Persistence with HIV Preexposure Prophylaxis in the United States, 2012-2017. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  M. Golden,et al.  A Pharmacist-Led, Same-Day, HIV Pre-Exposure Prophylaxis Initiation Program to Increase PrEP Uptake and Decrease Time to PrEP Initiation. , 2020, AIDS patient care and STDs.

[27]  Danya E Keene,et al.  "You Never Know What Could Happen": Women's Perspectives of Pre-Exposure Prophylaxis in the Context of Recent Intimate Partner Violence. , 2020, Women's health issues : official publication of the Jacobs Institute of Women's Health.

[28]  Frank H. Galvan,et al.  Predictors of Awareness, Accessibility and Acceptability of Pre-exposure Prophylaxis (PrEP) Among English- and Spanish-Speaking Latino Men Who have Sex with Men in Los Angeles, California , 2019, Journal of Immigrant and Minority Health.

[29]  S. Goodreau,et al.  Cost-Effectiveness of Pre-Exposure Prophylaxis Among Adolescent Sexual Minority Males. , 2019, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[30]  FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic , 2019, Case Medical Research.

[31]  E. Gardner,et al.  Same-Day HIV Pre-Exposure Prophylaxis (PrEP) Initiation During Drop-in Sexually Transmitted Diseases Clinic Appointments Is a Highly Acceptable, Feasible, and Safe Model that Engages Individuals at Risk for HIV into PrEP Care , 2019, Open forum infectious diseases.

[32]  P. Sullivan,et al.  Developing and Assessing the Feasibility of a Home-based Preexposure Prophylaxis Monitoring and Support Program , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  B. Dong,et al.  Implementation of pre-exposure prophylaxis at a community pharmacy through a collaborative practice agreement with San Francisco Department of Public Health. , 2019, Journal of the American Pharmacists Association : JAPhA.

[34]  D. Smith,et al.  HIV Preexposure Prophylaxis, by Race and Ethnicity — United States, 2014–2016 , 2018, MMWR. Morbidity and mortality weekly report.

[35]  M. Golden,et al.  Patient Disengagement From an HIV Preexposure Prophylaxis Program in a Sexually Transmitted Disease Clinic , 2018, Sexually transmitted diseases.

[36]  P. Sullivan,et al.  Beyond the Biomedical: Preexposure Prophylaxis Failures in a Cohort of Young Black Men Who Have Sex With Men in Atlanta, Georgia , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  R. Gandhi.  Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[38]  S. Golub,et al.  PrEP Stigma: Implicit and Explicit Drivers of Disparity , 2018, Current HIV/AIDS Reports.

[39]  T. Friebel,et al.  What We Do , 2015, The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association.

[40]  M. C. Zea,et al.  Promoting Pre-exposure Prophylaxis to Prevent HIV Infections Among Sexual and Gender Minority Hispanics/Latinxs. , 2017, AIDS education and prevention : official publication of the International Society for AIDS Education.

[41]  Aerielle M. Allen,et al.  Stigma and Conspiracy Beliefs Related to Pre-exposure Prophylaxis (PrEP) and Interest in Using PrEP Among Black and White Men and Transgender Women Who Have Sex with Men , 2017, AIDS and Behavior.

[42]  L. Metsch,et al.  Understanding HIV Care Provider Attitudes Regarding Intentions to Prescribe PrEP , 2015, Journal of acquired immune deficiency syndromes.

[43]  F. van Griensven,et al.  HIV pre-exposure prophylaxis and health and community systems in the Global South: Thailand case study , 2015, Journal of the International AIDS Society.

[44]  Effectiveness of Prevention Strategies to Reduce the Risk of Acquiring or Transmitting HIV December 2015 , 2015 .

[45]  A. Damico,et al.  The Coverage Gap: Uninsured Poor Adults in States that Do Not Expand Medicaid - An Update , 2014 .

[46]  J. Brooks,et al.  Updates of Lifetime Costs of Care and Quality-of-Life Estimates for HIV-Infected Persons in the United States: Late Versus Early Diagnosis and Entry Into Care , 2013, Journal of acquired immune deficiency syndromes.

[47]  Clinical disciplines.  Pre-Exposure Prophylaxis , 2010 .

[48]  D. Guenter,et al.  Rapid point-of-care HIV testing in community-based anonymous testing program: a valuable alternative to conventional testing. , 2008, AIDS patient care and STDs.

[49]  R. Harmon,et al.  From the Health Resources and Services Administration. , 1990, JAMA.